YU40203A - Orto-supstituisana bis-aril jedinjenja, koja sadrže azot, primenjena kao inhibitori kalijumovog kanala - Google Patents

Orto-supstituisana bis-aril jedinjenja, koja sadrže azot, primenjena kao inhibitori kalijumovog kanala

Info

Publication number
YU40203A
YU40203A YU40203A YUP40203A YU40203A YU 40203 A YU40203 A YU 40203A YU 40203 A YU40203 A YU 40203A YU P40203 A YUP40203 A YU P40203A YU 40203 A YU40203 A YU 40203A
Authority
YU
Yugoslavia
Prior art keywords
bisaril
ortho
compounds used
potassium channel
substituted nitrogen
Prior art date
Application number
YU40203A
Other languages
English (en)
Inventor
Stefan Peukert
Joachim Brendel
Horst Hemmerle
Heinz-Werner Kleemann
Original Assignee
Aventis Pharma Deutschland Gmbh,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh, filed Critical Aventis Pharma Deutschland Gmbh,
Publication of YU40203A publication Critical patent/YU40203A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na jedinjenja formule I, u kojima A1 do A8, R(1), R(2), R(3), R(4), R(30) i R(31) imaju značenja koja su navedena u patentnim zahtevima. Ova jedinjenja su naročito pogodna kao nove aktivne supstance protiv aritmija, specijano za lečenje i profilaksu aritmija srčane predkomore, na primer atrialne fibrilacije (AF) ili lepršanja srčane predkomore (atriales Flattern).[Compounds of formula (I) wherein A1 - A8, R(1), R(2), R(3), R(4), R(30) and R(31) have the meanings cited in the claims. Said compounds are particularly suitable for use as novel antiarrythmic substances, especially in the treatment and prophylaxis of atrial arrhythmia, for example, atrial fibrillation (AF) or atrial flutter.
YU40203A 2000-12-07 2001-11-24 Orto-supstituisana bis-aril jedinjenja, koja sadrže azot, primenjena kao inhibitori kalijumovog kanala YU40203A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10060807A DE10060807A1 (de) 2000-12-07 2000-12-07 Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
YU40203A true YU40203A (sh) 2006-05-25

Family

ID=7666129

Family Applications (1)

Application Number Title Priority Date Filing Date
YU40203A YU40203A (sh) 2000-12-07 2001-11-24 Orto-supstituisana bis-aril jedinjenja, koja sadrže azot, primenjena kao inhibitori kalijumovog kanala

Country Status (31)

Country Link
US (1) US6794377B2 (sh)
EP (1) EP1341764B1 (sh)
JP (1) JP4445198B2 (sh)
KR (1) KR100815070B1 (sh)
CN (1) CN1237052C (sh)
AR (1) AR033408A1 (sh)
AT (1) ATE297897T1 (sh)
AU (2) AU2189202A (sh)
BR (1) BR0116005A (sh)
CA (1) CA2436891C (sh)
CZ (1) CZ301923B6 (sh)
DE (2) DE10060807A1 (sh)
DK (1) DK1341764T3 (sh)
EE (1) EE05220B1 (sh)
ES (1) ES2242792T3 (sh)
HK (1) HK1066539A1 (sh)
HR (1) HRP20030448B1 (sh)
HU (1) HUP0302762A3 (sh)
IL (2) IL156312A0 (sh)
MX (1) MXPA03004966A (sh)
NO (1) NO325297B1 (sh)
NZ (1) NZ526294A (sh)
PL (1) PL207057B1 (sh)
PT (1) PT1341764E (sh)
RU (1) RU2275360C2 (sh)
SI (1) SI1341764T1 (sh)
SK (1) SK286056B6 (sh)
TW (1) TWI242005B (sh)
WO (1) WO2002046162A1 (sh)
YU (1) YU40203A (sh)
ZA (1) ZA200303931B (sh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1474395B1 (en) 2002-02-12 2007-10-17 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US20050054673A1 (en) * 2003-09-08 2005-03-10 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
KR100924610B1 (ko) * 2004-12-07 2009-11-02 이난타 파마슈티칼스, 인코포레이티드 3,6-비시클롤리드
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
JP4943429B2 (ja) * 2005-07-22 2012-05-30 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
AU2007245891B2 (en) * 2006-04-27 2012-10-18 Sanofi-Aventis Deutschland Gmbh Inhibitors of the TASK-1 and TASK-3 ion channel
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CN102471284A (zh) 2009-07-30 2012-05-23 弗·哈夫曼-拉罗切有限公司 作为p2x7调节剂的二氢嘧啶酮酰胺
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (sh) 2011-07-01 2018-04-28
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
WO2014183221A1 (en) * 2013-05-17 2014-11-20 The Centre For Drug Research And Development Resveratrol analogs and therapeutic uses thereof
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616002A (en) * 1984-11-09 1986-10-07 Ciba-Geigy Corporation Dihydro pyridine compounds, compositions and use
US5196537A (en) * 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
DE4430638A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
CA2334258A1 (en) 1998-06-05 1999-12-09 Icagen, Inc. Potassium channel inhibitors
WO2000012077A1 (en) * 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
ZA200303931B (en) 2004-03-24
CN1537102A (zh) 2004-10-13
CZ20031564A3 (cs) 2003-09-17
CZ301923B6 (cs) 2010-07-28
CN1237052C (zh) 2006-01-18
PL365318A1 (en) 2004-12-27
HK1066539A1 (en) 2005-03-24
ES2242792T3 (es) 2005-11-16
HRP20030448B1 (en) 2006-06-30
AU2002221892B2 (en) 2006-07-13
PT1341764E (pt) 2005-09-30
SI1341764T1 (en) 2005-10-31
TWI242005B (en) 2005-10-21
US6794377B2 (en) 2004-09-21
KR100815070B1 (ko) 2008-03-20
RU2275360C2 (ru) 2006-04-27
DK1341764T3 (da) 2005-10-17
HUP0302762A2 (hu) 2003-11-28
AU2189202A (en) 2002-06-18
IL156312A0 (en) 2004-01-04
MXPA03004966A (es) 2003-09-25
DE10060807A1 (de) 2002-06-20
JP2004515493A (ja) 2004-05-27
NO325297B1 (no) 2008-03-17
HUP0302762A3 (en) 2010-03-29
KR20030081344A (ko) 2003-10-17
HRP20030448A2 (en) 2005-04-30
EP1341764B1 (de) 2005-06-15
ATE297897T1 (de) 2005-07-15
IL156312A (en) 2009-05-04
SK6872003A3 (en) 2004-02-03
WO2002046162A1 (de) 2002-06-13
AR033408A1 (es) 2003-12-17
NO20032488L (no) 2003-08-04
NZ526294A (en) 2005-04-29
EE200300225A (et) 2003-08-15
CA2436891A1 (en) 2002-06-13
US20030060470A1 (en) 2003-03-27
SK286056B6 (sk) 2008-02-05
PL207057B1 (pl) 2010-10-29
CA2436891C (en) 2011-01-11
EE05220B1 (et) 2009-10-15
BR0116005A (pt) 2004-01-06
DE50106549D1 (de) 2005-07-21
JP4445198B2 (ja) 2010-04-07
NO20032488D0 (no) 2003-06-02
EP1341764A1 (de) 2003-09-10

Similar Documents

Publication Publication Date Title
YU40203A (sh) Orto-supstituisana bis-aril jedinjenja, koja sadrže azot, primenjena kao inhibitori kalijumovog kanala
NO20003600D0 (no) Kaliumkanal inhibitorer
DE69725153D1 (de) Kaliumkanal-blocker
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
UA87434C2 (ru) Циклоалкильные соединения в качестве ингибиторов функции калиевых каналов
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
WO2004062613A3 (en) Hiv integrase inhibitors
CA2348735A1 (en) Heterocyclic potassium channel inhibitors
UA66837C2 (uk) Похідні 3-гідроксі-4-арил-5-оксопіразоліну, які проявляють гербіцидну активність
PL373645A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
WO2005030129A3 (en) Quinoline potassium channel inhibitors
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
BG104575A (en) Matrix metalloprotease inhibitors
GB2324091A (en) Metalloproteinase inhibitors
AP2001002045A0 (en) FKBP inhibitors.
YU79602A (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
WO1998012190A3 (en) Phenoxathiin derivatives as inhibitors of monoamine oxidase
AU4302996A (en) Uracil derivatives
SE0002603D0 (sv) New compounds
HK1024872A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.